falsefalse

Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway - Episode 1

Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer

, ,

Panelists discuss how biomarker testing plays a critical role in hormone receptor–positive, HER2-negative advanced breast cancer, emphasizing the timing of testing, the relevance of specific genomic assays, and the significant impact on prognosis and treatment decisions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    Now Viewing
    EP. 1: Insights on Biomarker Testing in HR+/HER2- Advanced Breast Cancer
    EP. 2: First-Line Treatment Strategies for HR+/HER2- Advanced Breast Cancer
    EP. 3: Role of PI3K/AKT/PTEN Pathway in HR+/HER2- Advanced Breast Cancer
    EP. 4: Overview of the CAPItello-291 Trial
    EP. 5: Clinical Experience with Capivasertib
    EP. 6: Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy
    EP. 7: Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
    EP. 8: Best Practices in Managing Patients on Capivasertib

    Video content above is prompted by the following:

    1. Please discuss the role of biomarker testing in hormone receptor–positive, HER2-negative advanced breast cancer.
    • At what point during the disease course do you test for biomarkers?
    • What are the most clinically relevant genomic tests or biomarker assays, and how do the results influence prognosis and treatment?

    Related Content:

    Adverse Event Management in HR+/HER2– Advanced Breast Cancer: PI3K/AKT/PTEN Pathway
    Best Practices in Managing Patients on Capivasertib
    Managing Capivasertib Side Effects: Strategies for Educating, Monitoring, and Addressing Rash and Hyperglycemia
    Adverse Event Management: Strategies for Reducing Diarrhea Risk in Capivasertib Therapy
    x